medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 1

<< Back Next >>

Ann Hepatol 2012; 11 (1)

Prevalence and resistance pattern of genotype G and H in chronic hepatitis B and HIV co-infected patients in Mexico

Mata MJA, Arroyo ACI, Calderón GM, Cazares RS, Fuentes AJL, Arias FR, Gaytán MJ

Language: English
References: 27
Page: 47-51
PDF size: 73.93 Kb.


ABSTRACT

Objective. We estimated the prevalence and identified the resistance pattern of HBV genotypes H and G in HBV monoinfected and HIV co-infected patients. Material and methods. A cross-sectional prevalence and analytic study were performed in chronic hepatitis B patients at the Hospital de Infectología, La Raza National Medical Center in Mexico City. Chronic HBV monoinfected and HIV co-infected patients were included. HBeAg, HBV viral load and genetic analysis of mutations were collected; CD4+ cells count from HIV co-infected patients and HIV RNA were measured. We calculated the prevalence and exact 95% binomial confidence interval and the Odds ratios (OR) with 95% confidence intervals to assess the relationship between the presence of risk factors and HBV genotypes H or G. Results. We enrolled 77 patients, 67 men and 10 women with 37 HIV co-infected patients. The distribution of HBV genotypes was: HBV genotype H 55 (71% [95% CI 60% to 80%]), HBV genotype G 16 (20.7%), HBV genotype F 4 (5.1%) and HBV genotype A 2 (2.6%). The most frequent mutations presented in 8 HIV co-infected patients and one mono-infected patient with antiretroviral therapy (ART) experience were rtM204V and six of them showed genotype G (6/9). Mono-infected HBV patients exposed more probability to HBV genotype H than co-infected HIV patients OR 13.0 (CI 95% 3.40-49.79), p = 0.0001. In contrast co-infected patients presented less possibility to have genotype H, 0.56 (CI 95% 0.42-0.75). Conclusions. This study confirms the high prevalence of HBV genotype H in Mexico; furthermore, our results suggest that HBV genotype G predominates in co-infected patients. As well, rtM204V and rtL180M mutations are common in HBV-HIV co-infected patients with genotype G and ART experience.


REFERENCES

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.

  2. Thio C, Seaberg E, Skolasky R. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360: 1921-6.

  3. Orito E, Mizokami M. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Intervirology 2003; 46: 408-12.

  4. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643–50.

  5. Arauz-Ruiz P, Norder H, Robertson B, Magnius L. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83: 2059-73.

  6. Olinger CM, Jutavijittum P, Hübschen JM, Yousukh A, Samountry B, et al. Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis 2008; 14: 1777-80.

  7. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198: 489-503.

  8. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81: 67-74.

  9. Tanaka Y, Mizokami M. Genetic diversity of hepatitis B virus as an important factor associated with differences in clinical outcomes. J Infect Dis 2007; 195: 1-4.

  10. Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, et al. Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007; 195: 5-11.

  11. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003; 46: 329-38.

  12. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.

  13. Lee CM, Chen CH, Lu SN, Tung HD, Chou WJ, et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003; 38: 95-101.

  14. Alter M. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: 6-9.

  15. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078-88.

  16. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003; 17: 1649-57.

  17. Alvarado-Esquivel C, Sablon E, Conde-González CJ, Juarez- Figueroa L, Ruiz-Maya L, et al. Molecular analysis of hepatitis B virus isolates in Mexico: Predominant circulation of hepatitis B virus genotype H. World J Gastroenterol 2006; 12: 6540-5.

  18. Alvarado-Esquivel C, Carrera-Gracia MA, Conde-González CJ, Juárez-Figueroa L, Ruiz-Maya L, et al. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico. J Antimicrob Chemother 2006; 52: 221-3.

  19. Ohnuma H, Yoshikawa A, Mizoguchi H, Okamoto H. Characterization of genotype H hepatitis B virus strain identified for the first time from a Japanese blood donor by nucleic acid amplification test. J Gen Virol 2005; 86: 595-9.

  20. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.

  21. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, et al. A comparison of Entecavir and Lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.

  22. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.

  23. Lin CL, Liao LY, Liu CJ, Chen PJ, Lai MY, et al., Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. J Gastroenterol 2002; 37: 318-20.

  24. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE 4th, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37: 27-35.

  25. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reversetranscriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 2009; 199: 1275-85.

  26. Mink-Park Y, Tabor E, Sung-Kim B. Mutations of precore and proximal core regions of hepatitis B virus genome in serum of hepatocellular carcinoma patients. Hepatology Res 1999; 16: 49-58.

  27. Chudy M, Schmidt M, Czudai V, Scheiblauer H, Nick S, et al. Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology 2006; 44: 99-107.




2020     |     www.medigraphic.com